著者

下田 賢一郎 星野 輝彦 塩津 和則

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.41, no.9, pp.636-642, 2015-09-10 (Released:2016-09-10)

参考文献数

16

---

In the present study, we conducted a retrospective assessment of the abnormal liver and renal function test results of 156 orthopedic patients receiving sulbactam/cefoperazone (SBT/CPZ). We assessed aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase levels for liver function, and serum creatinine and estimated glomerular filtration rate level for renal function. Liver function parameters after the administration of SBT/CPZ showed significantly higher values than that observed before administration. The incidence of abnormal liver function in patients was 23.1% (n = 36). Almost all abnormal liver function test results were grade 1, although grade 2 abnormal AST and ALT levels occurred in 3.2% (n = 5) and 4.5% (n = 7) of patients, respectively. Abnormal liver function of 36 patients recovered after stopping SBT/CPZ administration. In factorial analyses of abnormal liver function test results after SBT/CPZ administration, the abnormal liver function group (n = 36) showed significantly higher AST and ALT values before administration than the normal liver function group (n = 120). In contrast, there were no significant changes in renal function before and after the administration of SBT/CPZ. These results suggest that SBT/CPZ frequently induce hepatic dysfunction. In particular, patients with high AST and ALT levels should be closely followed up to check for hepatic dysfunction caused by SBT/CPZ.